Stephen Hoge - Aug 29, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ James Dillon, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Aug 29, 2025
Transactions value $
-$7,708
Form type
4
Date filed
9/2/2025, 05:20 PM
Previous filing
Aug 29, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hoge Stephen President C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, as Attorney-in-Fact 2025-09-02 0001760669

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +651 +0.04% 1.45M Aug 29, 2025 Direct F1
transaction MRNA Common Stock Tax liability -$7.71K -315 -0.02% $24.47 1.45M Aug 29, 2025 Direct F2
holding MRNA Common Stock 4.12K Aug 29, 2025 By Valhalla, LLC
holding MRNA Common Stock 152K Aug 29, 2025 By Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -651 -33.3% $0.00 1.3K Aug 29, 2025 Common Stock 651 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.